Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis

Angiogenesis

Volumn 12, Issue 4, 2009, Pages 325-338

  Harfouche, Rania ^a   Basu, Sudipta ^a   Soni, Shivani ^a   Hentschel, Dirk M ^a   Mashelkar, Raghunath A ^a   Sengupta, Shiladitya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Nanoparticles; PI3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIODEGRADABILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTERNALIZATION; MELANOMA CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ZEBRA FISH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELLS, CULTURED; CHROMONES; DRUG CARRIERS; ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MORPHOLINES; NANOCAPSULES; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

DANIO RERIO;

EID: 71249093831     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-009-9154-4     Document Type: Article

References (40)

1. I Vivanco CL Sawyers 2002 The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer 2 489 501 10.1038/nrc839 1:CAS:528: DC%2BD38XkvFKltLs%3D 12094235
2. SR Datta A Brunet ME Greenberg 1999 Cellular survival: a play in three Akts Genes Dev 13 2905 2927 10.1101/gad.13.22.2905 1:CAS:528:DyaK1MXnvVCltLo%3D 10579998
3. L Shayesteh Y Lu WL Kuo R Baldocchi T Godfrey C Collins D Pinkel B Powell GB Mills JW Gray 1999 PIK3CA is implicated as an oncogene in ovarian cancer Nat Genet 21 99 102 10.1038/5042 1:CAS:528:DyaK1MXltlWjtw%3D%3D 9916799 (Pubitemid 29036292)
4. JA Engelman L Chen X Tan K Crosby AR Guimaraes R Upadhyay M Maira K McNamara SA Perera Y Song LR Chirieac R Kaur A Lightbown J Simendinger T Li RF Padera C García-Echeverría R Weissleder U Mahmood LC Cantley KK Wong 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 1351 1356 10.1038/nm.1890 1:CAS:528:DC%2BD1cXhsVWhu7rI 19029981
5. D Koul 2008 PTEN signaling pathways in glioblastoma Cancer Biol Ther 7 1321 1325 1:CAS:528:DC%2BD1cXhsVKms7%2FJ 18836294
6. T Petrocelli JM Slingerland 2001 PTEN deficiency: a role in mammary carcinogenesis Breast Cancer Res 3 356 360 10.1186/bcr322 1:CAS:528: DC%2BD38Xjs1amtw%3D%3D 11737885 (Pubitemid 34196360)
7. LS Steelman KM Stadelman WH Chappell S Horn J Bäsecke M Cervello F Nicoletti M Libra F Stivala AM Martelli JA McCubrey 2008 Akt as a therapeutic target in cancer Expert Opin Ther Targets 12 1139 1165 10.1517/14728222.12.9. 1139 1:CAS:528:DC%2BD1cXpslaltrc%3D 18694380
8. K Iwanaga Y Yang MG Raso L Ma AE Hanna N Thilaganathan S Moghaddam CM Evans H Li WW Cai M Sato JD Minna H Wu CJ Creighton FJ Demayo II Wistuba JM Kurie 2008 Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer Cancer Res 68 1119 1127 10.1158/0008-5472.CAN- 07-3117 1:CAS:528:DC%2BD1cXhvFemtbk%3D 18281487 (Pubitemid 351272230)
9. Y Horie A Suzuki E Kataoka T Sasaki K Hamada J Sasaki K Mizuno G Hasegawa H Kishimoto M Iizuka M Naito K Enomoto S Watanabe TW Mak T Nakano 2004 Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas J Clin Invest 113 1774 1783 1:CAS:528: DC%2BD2cXkvFyjsbs%3D 15199412
10. TL Yuan HS Choi A Matsui C Benes E Lifshits J Luo JV Frangioni LC Cantley 2008 Class 1A PI3K regulates vessel integrity during development and tumorigenesis Proc Natl Acad Sci U S A 105 9739 9744 10.1073/pnas.0804123105 1:CAS:528:DC%2BD1cXovVKntb4%3D 18621722 (Pubitemid 352031370)
11. S Sengupta LA Sellers RC Li E Gherardi G Zhao N Watson R Sasisekharan TP Fan 2003 Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis Circulation 107 2955 2961 10.1161/01.CIR.0000077501.19266.E5 12782568 (Pubitemid 36736639)
12. S Sengupta R Sasisekharan 2007 Exploiting nanotechnology to target cancer Br J Cancer 96 9 1315 1319 1:CAS:528:DC%2BD2sXkslyju7c%3D 17406364
13. F Yuan M Leunig SK Huang DA Berk D Papahadjopoulos RK Jain 1994 Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res 54 3352 1:CAS:528:DyaK2cXltFOmsr8%3D 8012948
14. NK Ibrahim N Desai S Legha P Soon-Shiong RL Theriault E Rivera B Esmaeli SE Ring A Bedikian GN Hortobagyi JA Ellerhorst 2002 Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 1038 1044 1:CAS:528:DC%2BD38XksVSqurg%3D 12006516
15. F Stavridi C Palmieri 2008 Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer Expert Rev Anticancer Ther 8 1859 1869 10.1586/14737140.8.12.1859 1:CAS:528:DC%2BD1cXhsVKgs7vO 19046106
16. S Basu R Harfouche S Soni G Chimote RA Mashelkar S Sengupta 2009 Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy Proc Natl Acad Sci U S A 106 19 7957 7961 10.1073/pnas.0902857106 1:CAS:528:DC%2BD1MXmt1amtrY%3D 19383798
17. CJ Vlahos WF Matter KY Hui RF Brown 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J Biol Chem 269 5241 5248 1:CAS:528:DyaK2cXjtFGit78%3D 8106507
18. S Nicoli M Presta 2007 The zebrafish/tumor xenograft angiogenesis assay Nat Protoc 2 2918 2923 10.1038/nprot.2007.412 1:CAS:528:DC%2BD2sXhtlSlsrzO 18007628
19. M Ferrari 2005 Cancer nanotechnology: opportunities and challenges Nature Rev Cancer 5 161 171 10.1038/nrc1566 1:CAS:528:DC%2BD2MXhslSnt7o%3D (Pubitemid 40314948)
20. D Peer JM Karp S Hong OC Farokhzad R Margalit R Langer 2007 Nanocarriers as an emerging platform for cancer therapy Nature Nanotech 2 751 760 10.1038/nnano.2007.387 1:CAS:528:DC%2BD2sXhtlyktL%2FI (Pubitemid 350223348)
21. SM Moghimi AC Hunter JC Murray 2005 Nanomedicine: current status and future prospects FASEB J 19 3 311 330 10.1096/fj.04-2747rev 1:CAS:528: DC%2BD2MXit1ygsLw%3D 15746175 (Pubitemid 40316520)
22. KS Soppimath T Aminabhavi AR Kulkarni WE Rudzinski 2001 Biodegradable polymeric nanoparticles as drug delivery devices J Controlled Release 70 1 260 10.1016/S0168-3659(00)00339-4 1:CAS:528:DC%2BD3MXovV2rtQ%3D%3D (Pubitemid 32144788)
23. M Honorat A Mesnier A Di Pietro V Lin P Cohen C Dumontet L Payen 2008 Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells Biochem Biophys Res Commun 375 308 314 10.1016/j.bbrc.2008.07.149 1:CAS:528:DC%2BD1cXhtFaqs73P 18692485
24. D Stokoe LR Stephens T Copeland PR Gaffney CB Reese GF Painter AB Holmes F McCormick PT Hawkins 1997 Dual role of phosphatidylinositol-3, 4, 5-trisphosphate in the activation of protein kinase B Science 277 567 570 10.1126/science.277.5325.567 1:CAS:528:DyaK2sXkvVCgtbs%3D 9228007 (Pubitemid 27369005)
25. SR Datta H Dudek X Tao S Masters H Fu Y Gotoh ME Greenberg 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91 231 241 10.1016/S0092-8674(00)80405-5 1:CAS:528: DyaK2sXntVyiu7k%3D 9346240 (Pubitemid 27456390)
26. MH Cardone N Roy HR Stennicke GS Salvesen TF Franke E Stanbridge S Frisch JC Reed 1998 Regulation of cell death protease caspase-9 by phosphorylation Science 282 1318 1321 10.1126/science.282.5392.1318 1:CAS:528:DyaK1cXnsFentLY%3D 9812896
27. A Brunet A Bonni MJ Zigmond MZ Lin P Juo LS Hu MJ Anderson KC Arden J Blenis ME Greenberg 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 857 868 10.1016/S0092- 8674(00)80595-4 1:CAS:528:DyaK1MXitFGgsr0%3D 10102273
28. E Buck A Eyzaguirre M Rosenfeld-Franklin S Thomson M Mulvihill S Barr E Brown M O'Connor Y Yao J Pachter M Miglarese D Epstein KK Iwata JD Haley NW Gibson QS Ji 2008 Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors Cancer Res 68 8322 8332 10.1158/0008-5472.CAN-07-6720 1:CAS:528:DC%2BD1cXht1Cmsb3M 18922904
29. S Grant 2008 Cotargeting survival signaling pathways in cancer J Clin Invest 118 3003 3006 10.1172/JCI36898E1 1:CAS:528:DC%2BD1cXhtV2isbzM 18725993
30. QB She DB Solit Q Ye KE O'Reilly J Lobo N Rosen 2005 Nanocarriers as an emerging platform for cancer therapy Cancer Cell 8 287 297 10.1016/j.ccr.2005. 09.006 1:CAS:528:DC%2BD2MXhtFOrtLrE 16226704 (Pubitemid 41443414)
31. CW Kinkade M Castillo-Martin A Puzio-Kuter J Yan TH Foster H Gao Y Sun X Ouyang WL Gerald C Cordon-Cardo C Abate-Shen 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 3051 3064 1:CAS:528:DC%2BD1cXhtV2isb3N 18725989
32. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 273 286 10.1038/nrd2115 1:CAS:528:DC%2BD2sXjs1SisL4%3D 17396134 (Pubitemid 46505878)
33. J Folkman 2002 Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 15 18 1:CAS:528:DC%2BD3sXlvFSqtg%3D%3D 12516034
34. G Gasparini R Longo M Toi N Ferrara 2005 Nanocarriers as an emerging platform for cancer therapy Nat Clin Pract Oncol 2 562 577 10.1038/ncponc0342 1:CAS:528:DC%2BD2MXht1Ghu77F 16270097 (Pubitemid 41721816)
35. S Sengupta LA Sellers T Cindrova J Skepper E Gherardi R Sasisekharan TP Fan 2003 Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis Cancer Res 63 8351 8359 1:CAS:528:DC%2BD3sXpvVagtLk%3D 14678996
36. CR Schnell F Stauffer PR Allegrini T O'Reilly PM McSheehy C Dartois M Stumm R Cozens A Littlewood-Evans C García-Echeverría SM Maira 2008 Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging Cancer Res 68 6598 6607 10.1158/0008-5472.CAN-08-1044 1:CAS:528:DC%2BD1cXpslKnu7w%3D 18701483
37. K Stoletov V Montel RD Lester SL Gonias R Klemke 2007 High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish Proc Natl Acad Sci U S A 104 17406 17411 10.1073/pnas.0703446104 1:CAS:528:DC%2BD2sXht1ymtrnE 17954920 (Pubitemid 350219851)
38. S Sengupta D Eavarone I Capila G Zhao N Watson T Kiziltepe R Sasisekharan 2005 Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 436 568 572 10.1038/nature03794 1:CAS:528: DC%2BD2MXmsFCgs70%3D 16049491 (Pubitemid 41112931)
39. G Kaul M Amiji 2004 Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model J Drug Target 12 585 591 10.1080/10611860400013451 1:CAS:528:DC%2BD2cXhtFCqurbP 15621684 (Pubitemid 40100706)
40. JD Hood M Bednarski R Frausto S Guccione RA Reisfeld R Xiang DA Cheresh 2002 Tumor regression by targeted gene delivery to the neovasculature Science 296 2404 10.1126/science.1070200 1:CAS:528:DC%2BD38XltFWksrk%3D 12089446 (Pubitemid 34734217)